Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 85

1.

JAK1/JAK2 inhibition by baricitinib in diabetic kidney disease: results from a Phase 2 randomized controlled clinical trial.

Tuttle KR, Brosius FC 3rd, Adler SG, Kretzler M, Mehta RL, Tumlin JA, Tanaka Y, Haneda M, Liu J, Silk ME, Cardillo TE, Duffin KL, Haas JV, Macias WL, Nunes FP, Janes JM.

Nephrol Dial Transplant. 2018 Feb 22. doi: 10.1093/ndt/gfx377. [Epub ahead of print]

PMID:
29481660
2.

IMMU-140, a Novel SN-38 Antibody-Drug Conjugate Targeting HLA-DR, Mediates Dual Cytotoxic Effects in Hematologic Cancers and Malignant Melanoma.

Cardillo TM, Govindan SV, Zalath MB, Rossi DL, Wang Y, Chang CH, Goldenberg DM.

Mol Cancer Ther. 2018 Jan;17(1):150-160. doi: 10.1158/1535-7163.MCT-17-0354. Epub 2017 Nov 13.

PMID:
29133623
3.

Selective and Concentrated Accretion of SN-38 with a CEACAM5-Targeting Antibody-Drug Conjugate (ADC), Labetuzumab Govitecan (IMMU-130).

Sharkey RM, Govindan SV, Cardillo TM, Donnell J, Xia J, Rossi EA, Chang CH, Goldenberg DM.

Mol Cancer Ther. 2018 Jan;17(1):196-203. doi: 10.1158/1535-7163.MCT-17-0442. Epub 2017 Oct 27.

PMID:
29079710
4.

Combination Therapy with Bispecific Antibodies and PD-1 Blockade Enhances the Antitumor Potency of T Cells.

Chang CH, Wang Y, Li R, Rossi DL, Liu D, Rossi EA, Cardillo TM, Goldenberg DM.

Cancer Res. 2017 Oct 1;77(19):5384-5394. doi: 10.1158/0008-5472.CAN-16-3431. Epub 2017 Aug 17.

PMID:
28819027
5.

Synthetic Lethality Exploitation by an Anti-Trop-2-SN-38 Antibody-Drug Conjugate, IMMU-132, Plus PARP Inhibitors in BRCA1/2-wild-type Triple-Negative Breast Cancer.

Cardillo TM, Sharkey RM, Rossi DL, Arrojo R, Mostafa AA, Goldenberg DM.

Clin Cancer Res. 2017 Jul 1;23(13):3405-3415. doi: 10.1158/1078-0432.CCR-16-2401. Epub 2017 Jan 9.

6.

Combining ABCG2 Inhibitors with IMMU-132, an Anti-Trop-2 Antibody Conjugate of SN-38, Overcomes Resistance to SN-38 in Breast and Gastric Cancers.

Chang CH, Wang Y, Zalath M, Liu D, Cardillo TM, Goldenberg DM.

Mol Cancer Ther. 2016 Aug;15(8):1910-9. doi: 10.1158/1535-7163.MCT-16-0219. Epub 2016 May 20.

7.

Baricitinib in Patients with Refractory Rheumatoid Arthritis.

Genovese MC, Kremer J, Zamani O, Ludivico C, Krogulec M, Xie L, Beattie SD, Koch AE, Cardillo TE, Rooney TP, Macias WL, de Bono S, Schlichting DE, Smolen JS.

N Engl J Med. 2016 Mar 31;374(13):1243-52. doi: 10.1056/NEJMoa1507247.

8.

Enhanced Delivery of SN-38 to Human Tumor Xenografts with an Anti-Trop-2-SN-38 Antibody Conjugate (Sacituzumab Govitecan).

Sharkey RM, McBride WJ, Cardillo TM, Govindan SV, Wang Y, Rossi EA, Chang CH, Goldenberg DM.

Clin Cancer Res. 2015 Nov 15;21(22):5131-8. doi: 10.1158/1078-0432.CCR-15-0670. Epub 2015 Jun 23.

9.

Trop-2 is a novel target for solid cancer therapy with sacituzumab govitecan (IMMU-132), an antibody-drug conjugate (ADC).

Goldenberg DM, Cardillo TM, Govindan SV, Rossi EA, Sharkey RM.

Oncotarget. 2015 Sep 8;6(26):22496-512.

10.

Sacituzumab Govitecan (IMMU-132), an Anti-Trop-2/SN-38 Antibody-Drug Conjugate: Characterization and Efficacy in Pancreatic, Gastric, and Other Cancers.

Cardillo TM, Govindan SV, Sharkey RM, Trisal P, Arrojo R, Liu D, Rossi EA, Chang CH, Goldenberg DM.

Bioconjug Chem. 2015 May 20;26(5):919-31. doi: 10.1021/acs.bioconjchem.5b00223. Epub 2015 May 8.

PMID:
25915780
11.

Improving the therapeutic index in cancer therapy by using antibody-drug conjugates designed with a moderately cytotoxic drug.

Govindan SV, Cardillo TM, Rossi EA, Trisal P, McBride WJ, Sharkey RM, Goldenberg DM.

Mol Pharm. 2015 Jun 1;12(6):1836-47. doi: 10.1021/mp5006195. Epub 2014 Nov 25.

PMID:
25402018
12.

Redirected T-cell killing of solid cancers targeted with an anti-CD3/Trop-2-bispecific antibody is enhanced in combination with interferon-α.

Rossi EA, Rossi DL, Cardillo TM, Chang CH, Goldenberg DM.

Mol Cancer Ther. 2014 Oct;13(10):2341-51. doi: 10.1158/1535-7163.MCT-14-0345. Epub 2014 Jul 22.

13.

Transferring from clopidogrel loading dose to prasugrel loading dose in acute coronary syndrome patients. High on-treatment platelet reactivity analysis of the TRIPLET trial.

Diodati JG, Saucedo JF, Cardillo TE, Jakubowski JA, Henneges C, Effron MB, Lipkin FR, Walker JR, Duvvuru S, Sundseth SS, Fisher HN, Angiolillo DJ.

Thromb Haemost. 2014 Aug;112(2):311-22. doi: 10.1160/TH13-09-0747. Epub 2014 Apr 10.

PMID:
24718367
14.

Trop-2-targeting tetrakis-ranpirnase has potent antitumor activity against triple-negative breast cancer.

Liu D, Cardillo TM, Wang Y, Rossi EA, Goldenberg DM, Chang CH.

Mol Cancer. 2014 Mar 10;13:53. doi: 10.1186/1476-4598-13-53.

15.

A new class of bispecific antibodies to redirect T cells for cancer immunotherapy.

Rossi DL, Rossi EA, Cardillo TM, Goldenberg DM, Chang CH.

MAbs. 2014 Mar-Apr;6(2):381-91. doi: 10.4161/mabs.27385. Epub 2013 Dec 2.

16.

Effect on platelet reactivity from a prasugrel loading dose after a clopidogrel loading dose compared with a prasugrel loading dose alone: Transferring From Clopidogrel Loading Dose to Prasugrel Loading Dose in Acute Coronary Syndrome Patients (TRIPLET): a randomized controlled trial.

Diodati JG, Saucedo JF, French JK, Fung AY, Cardillo TE, Henneges C, Effron MB, Fisher HN, Angiolillo DJ.

Circ Cardiovasc Interv. 2013 Oct 1;6(5):567-74. doi: 10.1161/CIRCINTERVENTIONS.112.000063. Epub 2013 Sep 24.

PMID:
24065443
17.

Interferon-λ1 linked to a stabilized dimer of Fab potently enhances both antitumor and antiviral activities in targeted cells.

Liu D, Chang CH, Rossi EA, Cardillo TM, Goldenberg DM.

PLoS One. 2013 May 16;8(5):e63940. doi: 10.1371/journal.pone.0063940. Print 2013.

18.

Targeting both IGF-1R and mTOR synergistically inhibits growth of renal cell carcinoma in vitro.

Cardillo TM, Trisal P, Arrojo R, Goldenberg DM, Chang CH.

BMC Cancer. 2013 Apr 1;13:170. doi: 10.1186/1471-2407-13-170.

19.

Milatuzumab-SN-38 conjugates for the treatment of CD74+ cancers.

Govindan SV, Cardillo TM, Sharkey RM, Tat F, Gold DV, Goldenberg DM.

Mol Cancer Ther. 2013 Jun;12(6):968-78. doi: 10.1158/1535-7163.MCT-12-1170. Epub 2013 Feb 20.

20.

Optimization of multivalent bispecific antibodies and immunocytokines with improved in vivo properties.

Rossi EA, Chang CH, Cardillo TM, Goldenberg DM.

Bioconjug Chem. 2013 Jan 16;24(1):63-71. doi: 10.1021/bc300488f. Epub 2012 Dec 21.

PMID:
23116517
21.

Prevention of acute graft-versus-host disease in a xenogeneic SCID mouse model by the humanized anti-CD74 antagonistic antibody milatuzumab.

Chen X, Chang CH, Stein R, Cardillo TM, Gold DV, Goldenberg DM.

Biol Blood Marrow Transplant. 2013 Jan;19(1):28-39. doi: 10.1016/j.bbmt.2012.09.015. Epub 2012 Sep 28.

22.

Evaluation of a novel hexavalent humanized anti-IGF-1R antibody and its bivalent parental IgG in diverse cancer cell lines.

Chang CH, Wang Y, Trisal P, Li R, Rossi DL, Nair A, Gupta P, Losman M, Cardillo TM, Rossi EA, Goldenberg DM.

PLoS One. 2012;7(8):e44235. doi: 10.1371/journal.pone.0044235. Epub 2012 Aug 31.

23.

A new Tri-Fab bispecific antibody for pretargeting Trop-2-expressing epithelial cancers.

Sharkey RM, van Rij CM, Karacay H, Rossi EA, Frielink C, Regino C, Cardillo TM, McBride WJ, Chang CH, Boerman OC, Goldenberg DM.

J Nucl Med. 2012 Oct;53(10):1625-32. doi: 10.2967/jnumed.112.104364. Epub 2012 Sep 5.

24.

A novel class of anti-HIV agents with multiple copies of enfuvirtide enhances inhibition of viral replication and cellular transmission in vitro.

Chang CH, Hinkula J, Loo M, Falkeborn T, Li R, Cardillo TM, Rossi EA, Goldenberg DM, Wahren B.

PLoS One. 2012;7(7):e41235. doi: 10.1371/journal.pone.0041235. Epub 2012 Jul 23.

25.

Dual-targeting immunotherapy of lymphoma: potent cytotoxicity of anti-CD20/CD74 bispecific antibodies in mantle cell and other lymphomas.

Gupta P, Goldenberg DM, Rossi EA, Cardillo TM, Byrd JC, Muthusamy N, Furman RR, Chang CH.

Blood. 2012 Apr 19;119(16):3767-78. doi: 10.1182/blood-2011-09-381988. Epub 2012 Jan 23.

26.

Epratuzumab-SN-38: a new antibody-drug conjugate for the therapy of hematologic malignancies.

Sharkey RM, Govindan SV, Cardillo TM, Goldenberg DM.

Mol Cancer Ther. 2012 Jan;11(1):224-34. doi: 10.1158/1535-7163.MCT-11-0632. Epub 2011 Oct 28.

27.

Preclinical studies on targeted delivery of multiple IFNα2b to HLA-DR in diverse hematologic cancers.

Rossi EA, Rossi DL, Cardillo TM, Stein R, Goldenberg DM, Chang CH.

Blood. 2011 Aug 18;118(7):1877-84. doi: 10.1182/blood-2011-03-343145. Epub 2011 Jun 16.

28.

Humanized anti-Trop-2 IgG-SN-38 conjugate for effective treatment of diverse epithelial cancers: preclinical studies in human cancer xenograft models and monkeys.

Cardillo TM, Govindan SV, Sharkey RM, Trisal P, Goldenberg DM.

Clin Cancer Res. 2011 May 15;17(10):3157-69. doi: 10.1158/1078-0432.CCR-10-2939. Epub 2011 Mar 3.

29.

Ranpirnase (frog RNase) targeted with a humanized, internalizing, anti-Trop-2 antibody has potent cytotoxicity against diverse epithelial cancer cells.

Chang CH, Gupta P, Michel R, Loo M, Wang Y, Cardillo TM, Goldenberg DM.

Mol Cancer Ther. 2010 Aug;9(8):2276-86. doi: 10.1158/1535-7163.MCT-10-0338. Epub 2010 Jul 27.

30.

Therapy of B-cell malignancies by anti-HLA-DR humanized monoclonal antibody, IMMU-114, is mediated through hyperactivation of ERK and JNK MAP kinase signaling pathways.

Stein R, Gupta P, Chen X, Cardillo TM, Furman RR, Chen S, Chang CH, Goldenberg DM.

Blood. 2010 Jun 24;115(25):5180-90. doi: 10.1182/blood-2009-06-228288. Epub 2010 Jan 25.

31.

CEACAM5-targeted therapy of human colonic and pancreatic cancer xenografts with potent labetuzumab-SN-38 immunoconjugates.

Govindan SV, Cardillo TM, Moon SJ, Hansen HJ, Goldenberg DM.

Clin Cancer Res. 2009 Oct 1;15(19):6052-61. doi: 10.1158/1078-0432.CCR-09-0586. Epub 2009 Sep 29.

32.

A new method to produce monoPEGylated dimeric cytokines shown with human interferon-α2b.

Chang CH, Rossi EA, Cardillo TM, Nordstrom DL, McBride WJ, Goldenberg DM.

Bioconjug Chem. 2009 Oct 21;20(10):1899-907. doi: 10.1021/bc9001773. Epub 2009 Sep 8.

PMID:
19736932
33.

CD20-targeted tetrameric interferon-alpha, a novel and potent immunocytokine for the therapy of B-cell lymphomas.

Rossi EA, Goldenberg DM, Cardillo TM, Stein R, Chang CH.

Blood. 2009 Oct 29;114(18):3864-71. doi: 10.1182/blood-2009-06-228890. Epub 2009 Aug 26.

34.

Hexavalent bispecific antibodies represent a new class of anticancer therapeutics: 1. Properties of anti-CD20/CD22 antibodies in lymphoma.

Rossi EA, Goldenberg DM, Cardillo TM, Stein R, Chang CH.

Blood. 2009 Jun 11;113(24):6161-71. doi: 10.1182/blood-2008-10-187138. Epub 2009 Apr 16.

35.

Properties and structure-function relationships of veltuzumab (hA20), a humanized anti-CD20 monoclonal antibody.

Goldenberg DM, Rossi EA, Stein R, Cardillo TM, Czuczman MS, Hernandez-Ilizaliturri FJ, Hansen HJ, Chang CH.

Blood. 2009 Jan 29;113(5):1062-70. doi: 10.1182/blood-2008-07-168146. Epub 2008 Oct 21. Erratum in: Blood. 2009 May 21;113(21):5368.

36.

Antibody conjugates of 7-ethyl-10-hydroxycamptothecin (SN-38) for targeted cancer chemotherapy.

Moon SJ, Govindan SV, Cardillo TM, D'Souza CA, Hansen HJ, Goldenberg DM.

J Med Chem. 2008 Nov 13;51(21):6916-26. doi: 10.1021/jm800719t. Epub 2008 Oct 22.

37.

Novel designs of multivalent anti-CD20 humanized antibodies as improved lymphoma therapeutics.

Rossi EA, Goldenberg DM, Cardillo TM, Stein R, Wang Y, Chang CH.

Cancer Res. 2008 Oct 15;68(20):8384-92. doi: 10.1158/0008-5472.CAN-08-2033.

38.

A novel bispecific, trivalent antibody construct for targeting pancreatic carcinoma.

Gold DV, Goldenberg DM, Karacay H, Rossi EA, Chang CH, Cardillo TM, McBride WJ, Sharkey RM.

Cancer Res. 2008 Jun 15;68(12):4819-26. doi: 10.1158/0008-5472.CAN-08-0232.

39.

Bispecific anti-CD20/22 antibodies inhibit B-cell lymphoma proliferation by a unique mechanism of action.

Qu Z, Goldenberg DM, Cardillo TM, Shi V, Hansen HJ, Chang CH.

Blood. 2008 Feb 15;111(4):2211-9. Epub 2007 Nov 19.

40.

CD74: a new candidate target for the immunotherapy of B-cell neoplasms.

Stein R, Mattes MJ, Cardillo TM, Hansen HJ, Chang CH, Burton J, Govindan S, Goldenberg DM.

Clin Cancer Res. 2007 Sep 15;13(18 Pt 2):5556s-5563s. Review.

41.

Yeast N(alpha)-terminal acetyltransferases are associated with ribosomes.

Polevoda B, Brown S, Cardillo TS, Rigby S, Sherman F.

J Cell Biochem. 2008 Feb 1;103(2):492-508.

PMID:
17541948
42.

Bispecific antibody pretargeting of tumor neovasculature for improved systemic radiotherapy of solid tumors.

Moosmayer D, Berndorff D, Chang CH, Sharkey RM, Rother A, Borkowski S, Rossi EA, McBride WJ, Cardillo TM, Goldenberg DM, Dinkelborg LM.

Clin Cancer Res. 2006 Sep 15;12(18):5587-95.

43.

Stably tethered multifunctional structures of defined composition made by the dock and lock method for use in cancer targeting.

Rossi EA, Goldenberg DM, Cardillo TM, McBride WJ, Sharkey RM, Chang CH.

Proc Natl Acad Sci U S A. 2006 May 2;103(18):6841-6. Epub 2006 Apr 24.

44.

New MUC1 serum immunoassay differentiates pancreatic cancer from pancreatitis.

Gold DV, Modrak DE, Ying Z, Cardillo TM, Sharkey RM, Goldenberg DM.

J Clin Oncol. 2006 Jan 10;24(2):252-8. Epub 2005 Dec 12.

PMID:
16344318
45.

Signal amplification in molecular imaging by pretargeting a multivalent, bispecific antibody.

Sharkey RM, Cardillo TM, Rossi EA, Chang CH, Karacay H, McBride WJ, Hansen HJ, Horak ID, Goldenberg DM.

Nat Med. 2005 Nov;11(11):1250-5. Epub 2005 Oct 30.

PMID:
16258537
46.

Pretargeting of carcinoembryonic antigen-expressing cancers with a trivalent bispecific fusion protein produced in myeloma cells.

Rossi EA, Chang CH, Losman MJ, Sharkey RM, Karacay H, McBride W, Cardillo TM, Hansen HJ, Qu Z, Horak ID, Goldenberg DM.

Clin Cancer Res. 2005 Oct 1;11(19 Pt 2):7122s-7129s.

47.

Improving the delivery of radionuclides for imaging and therapy of cancer using pretargeting methods.

Sharkey RM, Karacay H, Cardillo TM, Chang CH, McBride WJ, Rossi EA, Horak ID, Goldenberg DM.

Clin Cancer Res. 2005 Oct 1;11(19 Pt 2):7109s-7121s.

48.

Anti-CD74 antibody-doxorubicin conjugate, IMMU-110, in a human multiple myeloma xenograft and in monkeys.

Sapra P, Stein R, Pickett J, Qu Z, Govindan SV, Cardillo TM, Hansen HJ, Horak ID, Griffiths GL, Goldenberg DM.

Clin Cancer Res. 2005 Jul 15;11(14):5257-64.

49.

Identification of a Mu-9 (anti-colon-specific antigen-p)-reactive peptide having homology to CA125 (MUC16).

Modrak DE, Karacay H, Cardillo TM, Newsome G, Goldenberg DM, Gold DV.

Int J Oncol. 2005 Jun;26(6):1591-6.

PMID:
15870874
50.

Synergistic interaction between sphingomyelin and gemcitabine potentiates ceramide-mediated apoptosis in pancreatic cancer.

Modrak DE, Cardillo TM, Newsome GA, Goldenberg DM, Gold DV.

Cancer Res. 2004 Nov 15;64(22):8405-10.

Supplemental Content

Loading ...
Support Center